Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)
(Stock Code: 2225)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE: COOPERATION FRAMEWORK AGREEMENT

This announcement is made by Jinhai Medical Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with the updates on the recent development of the business of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 2 July 2025, Shanghai Jinhai Medical Technology Limited（上海今海醫療科技有限公司）("**Shanghai JH**"), a wholly-owned subsidiary of the Company, entered into a cooperation framework agreement (the "**Agreement**") for a term of five years with Ningbo Verykind Medical Device Co., Ltd.*（寧波維爾凱迪醫療器械有限公司）("**Verykind Medical**"), a wholly-owned subsidiary of Ningbo David Medical Device Co., Ltd.*（寧波戴維醫療器械股份有限公司）("**David Medical**", together with its subsidiaries, the "**David Medical Group**"), whose shares are listed on the A Share market of the Shenzhen Stock Exchange Growth Enterprise Market (stock code: 300314).

Pursuant to the Agreement, Shanghai JH and David Medical Group will strive for joint cooperation on endoscope products at international markets, with the aim to developing competitive high-end medical device solutions in the international market. The endoscope products will form a foundation for establishing a long term cooperation relationship between the parties. It is expected that when the cooperation progresses, Verykind Medical will have exclusive priority and the exclusive overseas distribution rights in respect of the rigid endoscope products（硬性內窺鏡產品）of the Group. Shanghai JH and David Medical Group will utilize their comparative advantages in production and sales of endoscope products to develop certain overseas market and will also enhance product delivery efficiency and cost competitiveness through optimizing resources allocation, supply chain collaboration and capacity linkage.

Shanghai JH will also cooperate with Verykind Medical to promote the registration of endoscope products in various countries and the application for international certifications to accelerate the internationalization of endoscope products, and conduct clinical research in multiple research centres for establishing an international academic exchange platform, aiming to strengthen the global academic influence of the endoscope products through medical education, technical training, and joint brand promotion.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, David Medical and Verykind Medical are independent third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

INFORMATION OF DAVID MEDICAL AND VERYKIND MEDICAL

David Medical was established in 1992 and is a national high-tech enterprise integrating independent research and development, production and sales of medical devices. The shares of David Medical are listed on the A Share market of the Shenzhen Stock Exchange Growth Enterprise Market (stock code: 300314). David Medical's product lines include pediatric and obstetric care equipment and minimally invasive surgical instruments. David Medical's technology, products and services are provided to more than 140 countries and regions all over the world.

Verykind Medical was established in 2012 and a wholly-owned subsidiary of David Medical. Verykind Medical is committed to the research and development, production, sales and service of high-tech products related to mechanical surgery and minimally invasive surgery through technical cooperation with international leading companies, aiming to provide clinicians with comprehensive solutions for mechanical surgery and minimally invasive surgery.

REASONS FOR AND BENEFITS OF THE AGREEMENT

The principal business of the Group includes the manufacturing of minimally invasive surgery medical products.

The Agreement was entered into based on the Group and David Medical Group's mutual understanding of international cooperation and collaboration, and will also focus on the production, sales and internationalisation of endoscope products. It is expected that the Agreement will assist in promoting the selling of the endoscope products manufactured by the Group and broaden the Group's income stream and eventually maximise the return to the shareholders of the Company.

The Board considers that the cooperation contemplated under the Agreement is entered into in the normal course of business of the Company, and the terms thereof are entered into on normal commercial terms, which are fair and reasonable. The entering into of the Agreement is in line with the Company's development strategy and is in the interests of the Company and its shareholders as a whole.

The terms of the cooperation contemplated under the Agreement are subject to the terms of any subsequent formal agreements that may be entered into between the Group and David Medical Group from time to time. As of the date of this announcement, the Company has not entered into any legally binding agreement with the David Medical Group in respect of any specific cooperation plan. If any transaction(s) under the Agreement materialises, such transaction(s) may constitute notifiable transaction(s) and/or connected transaction(s) under Chapter 14 and/or Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The Company will comply with the applicable requirements of the Listing Rules and will make further announcement(s) in accordance with the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 2 July 2025

As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.

* *For identification purposes only*